Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.
Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.
Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
--Lipocine Inc., a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc, Health Canada has approved TLANDO ® capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of...
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Detailed price information for Lipocine Inc (LPCN-Q) from The Globe and Mail including charting and trades.
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company management will present and meet with investors at the H.C. Wainwright 28th Annual Global Investment Conference, to be held in person and virtually September 14-16, 2026.
Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
This is the newest page. Registered accounts read further back.